What is the appropriate genetic testing criteria for breast cancer in the Chinese population?-Analysis of genetic and clinical features from a single cancer center database.
Sign Up to like & getrecommendations! Published in 2023 at "Cancer medicine"
DOI: 10.1002/cam4.5976
Abstract: BACKGROUND Genetic testing plays an important role in guiding screening, diagnosis, and precision treatment of breast cancer (BC). However, the appropriate genetic testing criteria remain controversial. The current study aims to facilitate the development of… read more here.
Keywords: appropriate genetic; genetic testing; brca lpvs; non brca ... See more keywords
Trap and kill strategy for non-BRCA mutant pancreatic cancer by co-delivery of olaparib and JQ1 with plectin-1 targeting peptide nanoparticles
Sign Up to like & getrecommendations! Published in 2020 at "Nano Today"
DOI: 10.1016/j.nantod.2020.100877
Abstract: Abstract The poly (ADP-ribose) polymerase (PARP) inhibitor olaparib (Ola), which inhibits the repair of DNA single-strand breaks, has been approved recently by the Food and Drug Administration (FDA) of U.S. for treatment of advanced pancreatic… read more here.
Keywords: non brca; delivery; pancreatic cancer; jq1 ... See more keywords
Abstract LB-A12: Results from the phase 3 study ARIEL3: mutations in non-BRCA homologous recombination repair genes confer sensitivity to maintenance treatment with the PARP inhibitor rucaparib in patients with recurrent platinum-sensitive high-grade ovarian carcinoma
Sign Up to like & getrecommendations! Published in 2018 at "Molecular Cancer Therapeutics"
DOI: 10.1158/1535-7163.targ-17-lb-a12
Abstract: Background: High-grade ovarian carcinomas (HGOC) with a mutation in BRCA1/2 or other core homologous recombination repair (HRR) genes are sensitive to treatment with the PARP inhibitor rucaparib. To study whether HRR gene mutations confer sensitivity… read more here.
Keywords: non brca; study; rucaparib; brca hrr ... See more keywords
Abstract CT165: A two-stage Simon Design phase II study for NOn-BRCA metastatic BReast cancer (MBC)patients with homologous recombination deficiency treated with OLAparib single agent.(NOBROLA study)
Sign Up to like & getrecommendations! Published in 2018 at "Cancer Research"
DOI: 10.1158/1538-7445.am2018-ct165
Abstract: BACKGROUND: Olaparib is a well-tolerated oral PARP inhibitor. Olaparib has shown promising monotherapy activity in patients with germline mutations in BRCA genes and cancers that exhibited a failure in DNA repair mechanism. The aim of… read more here.
Keywords: non brca; study; mbc; cancer ... See more keywords
Genetic testing and referral patterns of non-BRCA mutation carriers at increased or uncertain risk of ovarian cancer.
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2020.38.15_suppl.1585
Abstract: 1585Background: While the management of BRCA1/2 is clear, management of non-BRCA mutations with increased risk or uncertain risk of ovarian cancer (OC) is not well established. Previously, we repor... read more here.
Keywords: risk; non brca; risk ovarian; uncertain risk ... See more keywords
Pathologic Findings at Risk Reducing Surgery in BRCA and Non-BRCA Mutation Carriers: A Single-Center Experience
Sign Up to like & getrecommendations! Published in 2022 at "Diagnostics"
DOI: 10.3390/diagnostics12123054
Abstract: Risk-reducing surgery (RRS) is recommended in BRCA-mutated carriers because of their increased risk of developing ovarian cancer, while its role is still discussed for women harboring mutations in non-BRCA homologous repair genes. The aim of… read more here.
Keywords: surgery; mutation carriers; risk; non brca ... See more keywords